2017

ProNAi re-launched as Sierra Oncology

Tuesday, January 10, 2017

ProNAi Therapeutics, a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, has changed its corporate name to Sierra Oncology and that its shares will trade on the NASDAQ under the symbol SRRA. The company’s new name reflects its evolution into an oncology focused company advancing an emerging pipeline of promising therapies that target the DNA Damage Response (DDR) network.

[Read More]

MedUni Vienna is producing Big Data guidelines

Tuesday, January 10, 2017

MedUni Vienna is the lead partner in an international Big Data project for promoting the clinical investigation of hematological malignancies. The EU “HARMONY” project involves 51 partner institutions from eleven countries. MedUni Vienna—the domicile of the UNESCO Chair in Bioethics at the Josephinum—is developing ethical and legal guidelines for the handling of sensitive patient information. 

[Read More]

Kite Pharma, Fosun Pharma establish joint venture in China

Tuesday, January 10, 2017

Kite Pharma and Shanghai Fosun Pharmaceutical have announced a joint venture, Fosun Pharma Kite Biotechnology (company name subject to the approval of relevant registration authorities) to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two T cell receptor (TCR) product candidates from Kite. Axicabtagene ciloleucel (KTE-C19), Kite’s lead product candidate, is an investigational chimeric antigen receptor (CAR) T-cell therapy under development for the treatment of B-cell lymphomas and leukemias.

[Read More]

Illumina, Bio-Rad launch solution for single-cell genomic sequencing

Tuesday, January 10, 2017

Illumina and Bio-Rad Laboratories launched the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

[Read More]

Philips, Illumina partner on integrated genomics solutions for oncology

Monday, January 9, 2017

Royal Philips, a global leader in health technology, and Illumina, a global leader in DNA sequencing and array-based technologies, has announced a strategic collaboration that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. that want to develop precision medicine programs in oncology.

[Read More]

Mast Therapeutics, Savara to merge

Monday, January 9, 2017

Mast Therapeutics and Savara, a privately held emerging specialty pharmaceutical company focused on the treatment of rare respiratory diseases, have entered into a definitive merger agreement under which the stockholders of Savara would become the majority owners of Mast, and the operations of Mast and Savara would be combined. Subject to stockholder approval, the combined company will advance a pipeline of novel inhalation therapies for the treatment of diseases with significant unmet medical needs, featuring three product candidates, each in advanced clinical development.  

[Read More]